Want to see IN:NECLIFE full AI Analyst Report?

Nectar Lifesciences Ltd. (NECLIFE) Price & Analysis

1 Followers

NECLIFE Stock Chart & Stats

₹18.25

-₹0.79(-2.00%)

At close: Jan 08 4:00 PM EST

₹18.25

-₹0.79(-2.00%)

Day’s Range― - ―

52-Week Range₹9.20 - ₹23.70

Previous CloseN/A

Volume216.67K

Average Volume (3M)34.32K

Market Cap

₹2.30B

Enterprise Value₹1.23B

Total Cash (Recent Filing)₹139.72M

Total Debt (Recent Filing)₹4.59B

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-16.12

Shares Outstanding194,260,970

10 Day Avg. Volume25,321

30 Day Avg. Volume34,323

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.34

Price to Sales (P/S)97.56

P/FCF Ratio-0.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Pharma Business ModelNectar operates across APIs, finished dosages and contract manufacturing, giving multiple durable revenue streams and customer channels. This diversification supports resilience versus single-product firms, enables cross-selling and capacity leverage, and cushions demand swings over months.

Historically Moderate Leverage And Positive EquityDespite recent deterioration, historical debt-to-equity near 0.6–0.9 and a positive equity base provide a structural cushion. That balance sheet headroom can support refinancing, working-capital funding, or restructuring initiatives, reducing immediate insolvency risk over the medium term.

Prior Periods Of Positive Cash GenerationThe company has demonstrated an ability to generate operating and free cash flow in recent history, indicating operational capability and customer contracts that produced liquidity. That track record suggests recovery is operationally achievable if volumes and pricing normalize.

Bears Say

FY2026 Revenue Collapse And Large LossesA reported revenue collapse to zero and large net losses in FY2026 reflect a fundamental breakdown in sales or production. This destroys scale economics, erodes customer trust and margins, and creates persistent profitability risk unless underlying disruptions are addressed.

Sharp Cash Burn And Liquidity RiskVery large negative operating and free cash flow materially elevate financing needs. Persistent cash burn forces reliance on external funding or asset sales, can trigger covenant breaches, and constrains investment or remediation efforts, making operational recovery more difficult.

Steep Revenue And EPS DeteriorationSevere year-over-year declines in revenue (~-83%) and EPS (~-165%) point to structural demand loss or large operational setbacks. Such steep deterioration weakens pricing power, reduces reinvestment capacity, and raises the likelihood that market share and customer contracts have been permanently impaired.

Nectar Lifesciences Ltd. News

Nectar Lifesciences Files SEBI Dematerialisation Compliance Certificate for Q4 FY26

Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) has shared an announcement. Nectar Lifesciences Ltd. has notified the stock exchanges...

3M ago

Nectar Lifesciences Shareholders Clear Key Board and Governance Changes via Postal Ballot

Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) has issued an announcement. Nectar Lifesciences Ltd. has announced the results of...

4M ago

Nectar Lifesciences Says Subsidiary Inactive, Standalone and Consolidated Results Aligned

An update from Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) is now available. Nectar Lifesciences has clarified to the...

5M ago

Nectar Lifesciences Closes Trading Window Ahead of December Quarter Results

Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) just unveiled an update. Nectar Lifesciences Ltd. has announced that, in compliance...

6M ago

Nectar Lifesciences to Divest Capsule Unit to Capnest Health Care in INR 19.9 Crore Slump Sale

An announcement from Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) is now available. Nectar Lifesciences Ltd. has entered into...

7M ago

Nectar Lifesciences Announces Leadership Change and Share Buyback

Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) has shared an announcement. Nectar Lifesciences Ltd. announced the appointment of Mr....

7M ago

Nectar Lifesciences Announces Resignation of VP of Exports

The latest announcement is out from Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ). Nectar Lifesciences Ltd. announced the resignation...

8M ago

Nectar Lifesciences Ltd. Conducts 30th AGM with Emphasis on Stakeholder Engagement

An update from Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) is now available. Nectar Lifesciences Ltd. held its 30th...

9M ago

Nectar Lifesciences Ltd. Announces Virtual AGM for 2025

Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) has provided an announcement. Nectar Lifesciences Ltd. has announced that its 30th...

10M ago

Nectar Lifesciences Ltd. Publishes Q2 2025 Financial Results

Nectar Lifesciences Ltd. ( ($IN:NECLIFE) ) has provided an announcement. Nectar Lifesciences Ltd. has published its financial results...

11M ago

NECLIFE FAQ

What was Nectar Lifesciences Ltd.’s price range in the past 12 months?

Nectar Lifesciences Ltd. lowest stock price was ₹9.20 and its highest was ₹23.70 in the past 12 months.

What is Nectar Lifesciences Ltd.’s market cap?

Nectar Lifesciences Ltd.’s market cap is ₹2.30B.

When is Nectar Lifesciences Ltd.’s upcoming earnings report date?

Nectar Lifesciences Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 45 days.

How were Nectar Lifesciences Ltd.’s earnings last quarter?

Nectar Lifesciences Ltd. released its earnings results on May 30, 2026. The company reported -₹3.38 earnings per share for the quarter, missing the consensus estimate of N/A by -₹3.38.

Is Nectar Lifesciences Ltd. overvalued?

According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nectar Lifesciences Ltd. pay dividends?

Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of N/A. See more information on Nectar Lifesciences Ltd. dividends here

What is Nectar Lifesciences Ltd.’s EPS estimate?

Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nectar Lifesciences Ltd. have?

Nectar Lifesciences Ltd. has 194,260,970 shares outstanding.

What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?

Nectar Lifesciences Ltd. reported an EPS of -₹3.38 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.549%.

Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?

Currently, no hedge funds are holding shares in IN:NECLIFE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nectar Lifesciences Ltd.

Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.